Vradenburg: “What is good for science is good for patients”

Washington, DC (August 1, 2024) — The U.S. Senate Appropriations Committee approved a bill increasing our nation’s investment in Alzheimer’s research by $275 million for fiscal year 2025. 

“What is good for science is good for patients, and this bill represents strong bipartisan commitment to the fight against Alzheimer’s and the tens of millions of Americans who are affected by it,” said George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s. “A budget is a clear statement of our nation’s priorities, and it is evident this committee recognizes Alzheimer’s as a public health crisis that cannot be ignored. We thank Chair Murray, Vice Chair Collins, and all of the Senators on the committee who share our commitment to ending Alzheimer’s.”

Specifically, the Labor, Health and Human Services, Education, and Related Agencies Appropriations bill includes:

• $275 million increase for Alzheimer's disease research over fiscal year 2024
• $1.5 billion for the Advanced Research Projects Agency for Health (ARPA-H)
• $127 million for the Cures Act
• $122.8 billion in funding for the Department of Health and Human Services, an increase of $8 billion over fiscal year 2024
• $50.2 billion for the National Institutes of Health, an increase of more than $2 billion over 2024
• $173 million increase for top-line CDC funding

The appropriations bill now advances to the full Senate for a vote.

# # #

About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.